| Literature DB >> 29387659 |
Shrinivas-Shripatrao Chavan1, Vitthal D Kale1, Karthik N Rao1, Devkumar Rengaraja1, Amol Hekare1.
Abstract
INTRODUCTION: Since the days of Hippocrates, many modifications have been proposed in endonasal dacrocystorhinostomy (DCR), with the use of new drugs and implants showing variable results. The objective of this study was to analyze whether the use of silicon tubing or mitomycin C administration has an added advantage over conventional endonasal DCR.Entities:
Keywords: Conventional; Dacrocystitis; Endonasal dacrocystorhinostomy; Mitomycin C; Silicone tubing
Year: 2018 PMID: 29387659 PMCID: PMC5787650
Source DB: PubMed Journal: Iran J Otorhinolaryngol ISSN: 2251-7251
Fig 11A, Endoscopic image depicting elevated mucosal flap; 1B, Pictorial depiction of mucosal flap elevation S: Nasal Septum; MT: Middle Turbinate; F: Mucosal Flap; IT: Inferior Turbinate; LB: Lacrimal Bone
Fig 22A, Lacrimal probing with Bowman’s technique; 2B, Pictorial depiction of Bowman’s technique S: Nasal Septum; MT: Middle Turbinate; F: Mucosal Flap; IT: Inferior Turbinate; LP: Lacrimal Probe (Bowman
Fig 3Randomisation Flow Chart
Fig 4A, Silicon stent in lacrimal canaliculus; B, Endoscopic image of stent in nasolacrimal duct
Fig 53 months’ postoperative image showing stent in situ
Patient demographics
|
|
|
|
|---|---|---|
| Age (years) | ||
| 10–20 | 8 | 5.3% |
| 21–30 | 20 | 13.3% |
| 31–40 | 43 | 28.7% |
| 41–50 | 35 | 23.3% |
| 51–60 | 32 | 21.3% |
| 61–70 | 12 | 8.0% |
| Gender | ||
| Female | 98 | 65.3% |
| Male | 52 | 34.7% |
| Laterality | ||
| Left | 88 | 58.7% |
| Right | 45 | 30.0% |
| Bilateral | 17 | 11.3% |
| Symptoms | ||
| Epiphora | 150 | 100.0% |
| Nasal obstruction | 15 | 10.0% |
| Rhinitis | 15 | 10.0% |
| Sinusitis | 20 | 13.3% |
| Swelling over medial Canthus | 25 | 16.7% |
| Associated nasal pathology | ||
| Deviated nasal septum | 33 | 22.0% |
| Concha bullosa | 13 | 8.7% |
| Agger nasi cells | 10 | 6.7% |
| Accessory middle turbinate | 5 | 3.3% |
Postoperative patency using sac syringing under endoscopic vision
|
|
|
|
|
|---|---|---|---|
| Patients undergoing DCR using Mitomycin C | |||
| Day 7 | 50 | 50 | 100.0% |
| Day 15 | 50 | 50 | 100.0% |
| Day 30 | 50 | 46 | 88.9% |
| 3 months | 45 | 40 | 88.7% |
| 5 months | 30 | 26 | 86.7% |
| Patients undergoing endonasal DC R using silicon stent | |||
| Day 7 | 50 | 50 | 100.0% |
| Day 15 | 50 | 50 | 100.0% |
| Day 30 | 50 | 47 | 94.0% |
| 3 months | 50 | 45 | 90.0% |
| 5 months | 45 | 43 | 95.6% |
| Patients undergoing conventional endonasal DCR dacrocystorhinostomy | |||
| Day 7 | 50 | 50 | 100.0% |
| Day 15 | 50 | 47 | 94.0% |
| Day 30 | 50 | 46 | 92.1% |
| 3 months | 49 | 43 | 87.8% |
| 5 months | 38 | 32 | 84.2% |
Subjective improvement in epiphora
|
|
|
| ||
|---|---|---|---|---|
|
|
|
| ||
| Grade 0 | 26 (86.7%) | 47 (94.0%) | 32 (84.2%) | 105 (89.0%) |
| Grade 1 | 0 | 0 | 0 | 0 |
| Grade 2 | 0 | 0 | 0 | 0 |
| Grade 3 | 0 | 0 | 0 | 0 |
| Grade 4 | 04 (13.3%) | 03 (6.1%) | 6 (15.8%) | 13 (11.0%) |
| Grade 5 | 0 | 0 | 0 | 0 |
Complications
|
|
|
| ||
|---|---|---|---|---|
|
|
|
| ||
| Group I | 2 (4.0%) | 3 (6.0%) | 2 (4.0%) | 7 (14.0%) |
| Group II | 6 (12.0%) | 2 (4.0%) | 1 (2.0%) | 9 (18.0%) |
| Group III | 4 (8.0%) | 4 (8.0%) | 2 (4.0%) | 10 (20.0%) |
| Total | 12 (24.0%) | 9 (18.0%) | 5 (10.0%) | 26 (17.3%) |